SEC Form 4 · accession 0002081359-26-000008
Keros Therapeutics, Inc. · KROS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lorena Raquel Lerner
Officer — Chief Scientific Officer
Period of report
Aug 18, 2026
Accepted (ET)
Aug 20, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001664710
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 18, 2026 | S | 3,568 | $10.29 | D | 27,559 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.